Purified plasminogen activating factor produced by malignant lymphoid cells abrogates lymphocyte cytotoxicity.
Clin Exp Immunol
; 56(3): 701-8, 1984 Jun.
Article
em En
| MEDLINE
| ID: mdl-6430612
ABSTRACT
Immunosuppression is a generally observed phenomenon in patients with malignancies. Here we report that plasminogen activating factor (PAF) produced by human (P3HR-1) and simian (B95-8) lymphoid cells of malignant origin abrogates lymphocyte cytotoxicity. PAF has been purified from Epstein-Barr (EB) virus genome carrying lymphocyte cytotoxicity. PAF has been purified from Epstein-Barr (EB) virus genome carrying lymphoid lines by affinity chromatography using lysine-Sepharose columns. Purified PAF consistently inhibited Killer cell activity against the following targets K-562, EB virus superinfected Raji cells and in vitro EB virus transformed autologous B lymphocytes. Furthermore PAF also inhibited the antibody-dependent cellular cytotoxicity. The results presented also indicate that PAF affects the effector lymphocytes and not the target cells. Taken together, these observations emphasize the importance of factors such as PAF, released by malignant cells, as inhibitors/modulators of immune mechanisms effective against tumour cells.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Células Matadoras Naturais
/
Ativadores de Plasminogênio
/
Linfoma de Burkitt
/
Citotoxicidade Celular Dependente de Anticorpos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Clin Exp Immunol
Ano de publicação:
1984
Tipo de documento:
Article